ACLARION INC (ACON) Stock News
NASDAQ:ACON - Nasdaq - US6551872012 - Common Stock
ACON Latest News and Analysis
Get insights into the top gainers and losers of Tuesday's after-hours session.
Get insights into the top gainers and losers of Tuesday's after-hours session.
The trading volume of these stocks is deviating from the norm in today's session.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and Warrants
BROOMFIELD, CO - January 17, 2025 (NEWMEDIAWIRE) - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of an underwritten public offering of 100,000 shares of common stock and 143,900,000 pre-funded warrants with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $0.20 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $0.20 per share. The combined public offering price of each share of common stock together with the accompanying series A and series B common warrants is $0.10, and the combined public offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $0.09999. In addition, the Company granted to the underwriter a 45 day option to purchase up to an additional 21,000,000 shares of its common stock (or pre-funded warrants), at the public offering price, less underwriting discounts and commissions, and up to an additional 21,000,000 series A common warrants and up to an additional 21,000,000 series B common warrants at a nominal price to cover over-allotment sales. The underwriter exercised its option to purchase 21,000,000 series A common warrants and 21,000,000 series B common warrants. All shares of common stock, pre-funded warrants, series A common warrants and series B common warrant were sold by Aclarion. The closing of the public offering occurred on January 16, 2025.
Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and Warrants
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Which stocks are most active on Thursday?
Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!
Discover the most active stocks in Wednesday's session. Stay informed about the stocks that are generating the most trading volume!
Curious about the most active stocks on Wednesday? Find out which stocks are dominating the market action!
Top movers in Wednesday's session
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Which stocks are gapping on Wednesday?
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Aclarion Announces Pricing of $14.4 Million Public Offering of Common Stock and Warrants
BROOMFIELD, CO - January 15, 2025 (NEWMEDIAWIRE) - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the pricing of an underwritten public offering of approximately 144,000,000 shares of common stock (or pre-funded warrants in lieu thereof) with each share of common stock (or pre-funded warrant) accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $0.20 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $0.20 per share. The combined public offering price of each share of common stock together with the accompanying series A and series B common warrants is $0.10, and the combined public offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $0.09999. The Company also granted the underwriter a 45 day option to purchase up to 21,000,000 additional shares of common stock (or pre-funded warrants), up to 21,000,000 series A common warrants and up to 21,000,000 series B common warrants, to cover over-allotments. The closing of the public offering is expected to occur on or about January 16, 2025, subject to the satisfaction of customary closing conditions.
Aclarion Announces Pricing of $14.4 Million Public Offering of Common Stock and Warrants
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks in Tuesday's session
On Monday, there are stocks with unusual volume. Let's take a look.
Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.
These stocks are moving in today's session
Which stocks are experiencing notable movement on Monday?
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
These stocks are moving in today's pre-market session
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
These stocks are moving in today's after hours session
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the Market
BROOMFIELD, CO - (NewMediaWire) - January 3, 2025 - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it has agreed to sell 3,380,276 shares of its common stock at a price per share of $0.142 in a registered direct offering priced at the market. All of the shares of common stock in the offering are being sold by Aclarion. The closing of the offering is expected to take place on or about January 6, 2025, subject to the satisfaction of customary closing conditions.
Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Most active stocks in Friday's session
Discover the most active stocks in Friday's session. Stay informed about the stocks that are generating the most trading volume!
Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash
Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients MAGNETOM Flash is a...
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the...
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of...
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with...
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion, Inc.’s (NASDAQ: ACON) Emerging Role in the Back Pain Management Sector
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment...
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response
Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important...
Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey
CLUE is a Multi-center Trial to Identify how Often Nociscan’s AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr....
Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans
Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data ...
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company...